Focus on zafirlukast: A leukotriene receptor antagonist for the prophylaxis and chronic treatment of asthma

Formulary

Volumn 31, Issue 11, 1996, Pages 1029-1052

  Baldinger, Sandra L ^a   Shore, Eric T ^b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2342501944     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. McFadden ER, Gilbert IA, Asthma. N Engl J Med 1992;327:1928-37.
2. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992;326: 862-6.
3. Bone RC. Asthma: New treatments will improve disease management. Clin Pulm Med 1995;2.249-57.
4. Chanarin N, Johnston SL. Leukotrienes as a target in asthma therapy. Drugs 1994;47:12-24.
5. Professional Information Brochure. Accolate Tablets, Zeneca Pharmaceuticals, Wilmington, DE, September 1996.
6. Dahlén B, Zetterström O, Björck T, Dahlén S-E. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994;7:324-31.
7. Kemp JP, Glass M, Minkwitz MC. Onset of action of the leukotriene-receptor antagonist, zafirlukast (Accolate), in patients with asthma (abstract 844). The 51st Annual meeting of the American Academy of Allergy and Immunology, New York City, March 1995.
8. 4 receptor antagonist ICI-204,219. Am Rev Respir Dis 1990;141: 988-92.
9. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89:1040-5.
10. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337:690-4.
11. 4-receptor antagonist, ICI 204,219 on cold-air-induced bronchoconstriction in patients with asthma (abstract 794). The 50th Annual meeting of the American Academy of Allergy and Immunology, Anaheim, March 1994.
12. 4 antagonist. Am Rev Respir Dis 1992; 145:746-9.
13. 2)-induced bronchoconstriction in patients with asthma (abstract 41). The American Thoracic Society 1995 International Conference, Seattle, May 1995.
14. Calhoun WJ, Lavins BJ, Glass M. Effect of Accolate (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovocation (SBP) in patients with mild to moderate asthma (abstract). Am J Respir Crit Care Med 1995;151-A42.
15. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
16. Spector S, Miller CJ, Glass M. 13-week dose-response study with accolate (zafirlukast) in patients with mild to moderate asthma (abstract A379). The American Thoracic Society 1995 International Conference, Seattle, May 1995.
17. Lockey RF, Lavins BJ, Snader MS, Effects of 13 weeks of treatment with ICI 204,219 (Accolate) in patients with mild to moderate asthma (abstract 839). The 51st Annual meeting of the American Academy of Allergy and Immunology, New York City, March 1995.
18. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (Accolate) or cromolyn sodium (Intal) in patients with mild to moderate asthma (abstract 990). The 51st Annual meeting of the American Academy of Allergy and Immunology, New York City, March 1995.
19. F-D-C Reports - "The Pink Sheet," April 1, 1996, p19-20.
20. 4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995,151: 1734-9.
21. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993;147: 1413-18.
22. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993;147:1431-5.
23. Tashkin DP, Nelson HS, Cohn J, et al. Efficacy and safety of zafirlukast (Accolate) in patients with mild-to-moderate asthma (abstract). Am J Respir Crit Care Med 1996;153:A534.
24. F-D-C Reports -"The Pink Sheet," May 27, 1996 T&G 10-11.
25. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. Global Initiative for Asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 1995 US Department of Health and Human Services Publication 95-3659.